



**Genzyme Corporation**

500 Kendall Street  
Cambridge, MA 02142  
Tel 800.745.4447

November 17, 2010

**Re: Important Update Regarding Supply of Cerezyme® (imiglucerase for injection)**

Dear Healthcare Provider,

You may have heard in the news recently that Cerezyme production is proceeding successfully. In fact, recent manufacturing runs for Cerezyme have been above historical levels, allowing us to return to a more normal supply situation. Therefore, we are pleased to tell you that in the US:

- We have accommodated all requests received to date for patients wishing to start or re-start Cerezyme treatment.
- Patients may start or re-start Cerezyme at any time.
- We are now able to accommodate dose increases, and physicians may adjust prescriptions (dose and/or frequency) as appropriate. However, please remember that adjustments to the total monthly Cerezyme usage per patient should be made in 400-unit increments in order to avoid discarding partially used vials.

In order to expedite the ordering or dose adjustment process, health care providers can request to initiate treatment with Cerezyme or change a currently prescribed dose by completing the form available at [www.Cerezyme.com/request](http://www.Cerezyme.com/request). We will continue to ship Cerezyme one infusion at a time.

As you know, we continue to have limited inventory reserves of Cerezyme. Because of this, changes or delays in our manufacturing could lead to delays in the availability of Cerezyme. We will do our best to notify you promptly if there are any delays.

We at Genzyme want to say once again how much we appreciate your support as well as that of the entire Gaucher community, as we have worked over the past year to restore full, reliable supply of Cerezyme.

Please let us know if you have any questions or other feedback for Genzyme. You may contact Genzyme Medical Information at 1-800-745-4447, Option 2. Best wishes for a Happy Thanksgiving and a healthy and happy end of 2010 from the entire team here at Genzyme.

Sincerely,

Daniel Gruskin, MD  
Senior Director, US Medical Affairs  
Genzyme Corporation

Grannum Sant, MD  
Vice President, Global Medical Affairs  
Genzyme Corporation



**Genzyme Corporation**

500 Kendall Street  
Cambridge, MA 02142  
Tel 800.745.4447

November 17, 2010

**RE: Important Update Regarding Supply of Cerezyme® (imiglucerase for injection)**

Dear [Patient's Name],

You may have heard in the news recently that Cerezyme production is proceeding successfully. In fact, recent manufacturing runs for Cerezyme have been above historical levels, allowing us to return to a more normal supply situation. Therefore, I am pleased to tell you that in the US:

- We have accommodated all requests to date for patients wishing to start or re-start Cerezyme treatment.
- Patients may start or re-start Cerezyme at any time.
- We no longer need to restrict dose increases for patients currently receiving Cerezyme. Your physician may adjust your prescription (dose and/or frequency) as he/she sees fit.

Please speak to your physician if you have any questions about your Cerezyme treatment plan or if you wish to start or re-start treatment.

As you know, we have limited inventory reserves of Cerezyme. Because of this, changes or delays in our manufacturing could lead to delays in the availability of Cerezyme. We will do our best to notify you promptly if there are any delays.

I would like to say once again how much we appreciate your support as well as that of the entire Gaucher community, as we have worked over the past year to restore full, reliable supply of Cerezyme.

Please let me know if you have any questions related to this supply update or any feedback for Genzyme.

As the holiday season approaches, our thoughts are with you and your families. Best wishes for a Happy Thanksgiving and a healthy and happy end of 2010 from the entire team here at Genzyme.

Sincerely,

Your Case Manager,  
[Case Manager Name]  
[Phone]  
[Email]